Deep Brain Stimulation In The Treatment Of Severe Depression
Funder
National Health and Medical Research Council
Funding Amount
$1,008,087.00
Summary
Some patients with depression fail to respond to a variety of standard treatments and in this group, deep brain stimulation (DBS) is being evaluated as an alternative treatment option. This study will investigate the use of DBS applied to a novel brain target site in patients with highly treatment refractory depression.
Deep Brain Stimulation For Treatment Resistant Major Depression: Neural Correlates And Neuropsychological Outcomes
Funder
National Health and Medical Research Council
Funding Amount
$257,561.00
Summary
Major depression is a prevalent and devastating mental illness. While there are numerous pharmacological and psychological antidepressant therapies available, many patients do not respond to these treatments. Deep Brain Stimulation (DBS) is emerging as a potential treatment option for individuals with chronic severe treatment resistant major depression. The current project will investigate the cognitive and neurobiological outcomes associated with the use of DBS to treat depression.
Melanoma is the 4th most common cancer diagnosed in Australia. Advanced melanoma frequently spreads to other organs and can acquire resistance to anti-melanoma treatments, making it fundamentally incurable. I am focused on investigating the mechanisms underlying melanoma disease progression. I will achieve this by comparing the biological nature of melanoma cells at different stages of disease and therapy-resistance to identify new targets for the more effective treatment of patients with melano ....Melanoma is the 4th most common cancer diagnosed in Australia. Advanced melanoma frequently spreads to other organs and can acquire resistance to anti-melanoma treatments, making it fundamentally incurable. I am focused on investigating the mechanisms underlying melanoma disease progression. I will achieve this by comparing the biological nature of melanoma cells at different stages of disease and therapy-resistance to identify new targets for the more effective treatment of patients with melanoma.Read moreRead less
Optimising The Diagnosis And Management Of Treatment Refractory Benign Positioning Vertigo
Funder
National Health and Medical Research Council
Funding Amount
$286,466.00
Summary
Benign Positioning Vertigo, the most common and correctable cause of dizziness, is caused by freely floating calcium carbonate crystals in the semicircular canals of the inner ear. Localizing the affected semicircular canal holds the key to effective treatment.A proportion of sufferers will not respond to conventional repositioning treatments due to incorrect diagnoses. This study will explore refractory BPV in detail, develop test methods that accurately localize the affected canal and devise t ....Benign Positioning Vertigo, the most common and correctable cause of dizziness, is caused by freely floating calcium carbonate crystals in the semicircular canals of the inner ear. Localizing the affected semicircular canal holds the key to effective treatment.A proportion of sufferers will not respond to conventional repositioning treatments due to incorrect diagnoses. This study will explore refractory BPV in detail, develop test methods that accurately localize the affected canal and devise treatments for resistant BPV subtypes.Read moreRead less
Targeting A Master Regulator Of Tumour Cell Plasticity As A New Adjuvant Therapy For Prostate Cancer
Funder
National Health and Medical Research Council
Funding Amount
$780,338.00
Summary
Prostate cancer (PCa) claims the lives of over 3,000 Australian men each year. This highlights the urgent need to identify new molecular targets that can be developed as additional therapies for men with PCa. Our team has identified the protein, Zeb1, to be highly expressed in aggressive and treatment resistant forms of PCa. This study aims to characterise the role of Zeb1 in the lethal progression of PCa and to develop a new therapeutic agent to inhibit the production of ZEB1 by cancer cells.
Early Intervention For Treatment-resistant Conduct Disorder In Children
Funder
National Health and Medical Research Council
Funding Amount
$694,280.00
Summary
Conduct problems (CP) in childhood are the most reliable precursor of all types of adult mental health problems. Conclusive evidence now exists to show that a subgroup within CP children, those with high levels of callous-unemotional (CU) traits are etiologically distinct and are relatively unresponsive to existing evidence-based treatments.The aim of the current programme is to test a new treatment for these children.
A Randomised Controlled Trial Of Magnetic Seizure Therapy In Major Depressive Disorder
Funder
National Health and Medical Research Council
Funding Amount
$372,049.00
Summary
Electroconvulsive therapy (ECT) is the only established treatment for a substantial sub-population of patients who fail to respond to other therapies. However, there are significant complications of ECT including memory related side-effects. The aim of this study is to evaluate the clinical efficacy of a new form of treatment for severe depression, magnetic seizure therapy, which appears to have a substantially reduced rate of cognitive side-effects.
Deciphering Tumour Heterogeneity Of Breast Cancer Metastases Using Barcoded Patient Derived Xenografts
Funder
National Health and Medical Research Council
Funding Amount
$583,161.00
Summary
Breast cancer mortality is largely due to metastases that seed from the primary tumour. Breast tumours are known to contain a heterogeneous mix of cells, but the precise way that cells are selected for tumour growth and metastasis (as well as their response to systemic therapy) is not well understood. In this study we will use patient samples and cellular ‘barcoding’ to track the destiny of every single clone throughout disease progression and study the effect of various therapies on metastasis.
N-Acetyl Cysteine In Schizophrenia Resistant To Clozapine: A Double-Blind Randomised Placebo-Controlled Trial Targeting Negative Symptoms
Funder
National Health and Medical Research Council
Funding Amount
$981,789.00
Summary
Many patients with schizophrenia remain treatment resistant even after “last resort” medications like clozapine. This proposal will conduct a novel multi-site randomised placebo controlled trial of adjunctive N-acetyl cysteine in patients with clozapine resistant schizophrenia. Treatment efficacy will be examined at 8, 26 and 52 weeks.
Targeting Survival Pathways To Overcome The Resistance Of Human Melanoma To Treatment
Funder
National Health and Medical Research Council
Funding Amount
$332,123.00
Summary
Melanoma is a major Australian health problem. This is believed to be due to resistance of melanoma cells to cell death associated with inappropriate activation of survival signalling pathways. My previous studies have provided a number of insights into resistance mechanisms of melanoma cells to apoptosis. I wish to understand more fully the molecular basis of the survival signalling pathways, and to identify new therapeutic targets for overcoming resistance of melanoma to treatment.